AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments.
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSEABBV), saying it's “just a gem” and a “winner.” He added, “I can't believe the stock dropped so much.”
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Under the surface, markets remain preoccupied with the potential impact of tariffs, shifting inflation expectations, and the Federal Reserve’s policy trajectory.
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.
Pharmaceutical company AbbVie (NYSEABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share was 4.3% below analysts’ consensus estimates.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
